Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-16-1170PMID 27550451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin‐34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment

  2015cited by this paper
• IL-34 is a Treg-specific cytokine and mediates transplant tolerance.

  2015cited by this paper
• Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.

  2015cited by this paper
• Activation of the Interleukin-34 Inflammatory Pathway in Response to Influenza A Virus Infection

  2015cited by this paper
• Interleukin 34: a new modulator of human and experimental inflammatory bowel disease

  2015cited by this paper
• Macrophages and therapeutic resistance in cancer.

  2015influential reference
• Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies.

  2014cited by this paper
• Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

  2014cited by this paper
• Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

  2014cited by this paper
• NOD-Rag2null IL-2Rγnull Mice: An Alternative to NOG Mice for Generation of Humanized Mice

  2014cited by this paper
• Tumor-associated macrophages: from mechanisms to therapy.

  2014influential reference
• Colony-stimulating factor 1 potentiates lung cancer bone metastasis

  2014cited by this paper
• Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation

  2014cited by this paper
• PI3K/AKT signaling pathway and cancer: an updated review

  2014cited by this paper
• Tumor necrosis factor-α induces interleukin-34 expression through nuclear factor-κB activation in MC3T3-E1 osteoblastic cells

  2014cited by this paper
• Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFβ in claudin-low breast tumor cells

  2014cited by this paper
• IL-34 and CSF-1: similarities and differences

  2013cited by this paper
• Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

  2013cited by this paper
• Clinical significance of macrophage heterogeneity in human malignant tumors

  2013cited by this paper
• Macrophage regulation of tumor responses to anticancer therapies.

  2013cited by this paper
• Macrophage biology in development, homeostasis and disease

  2013influential reference
• Cancer drug resistance: an evolving paradigm

  2013cited by this paper
• IL-34 Induces the Differentiation of Human Monocytes into Immunosuppressive Macrophages. Antagonistic Effects of GM-CSF and IFNγ

  2013cited by this paper
• Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy

  2013cited by this paper
• The Newly Discovered Cytokine IL-34 Is Expressed in Gingival Fibroblasts, Shows Enhanced Expression by Pro-Inflammatory Cytokines, and Stimulates Osteoclast Differentiation

  2013cited by this paper
• Origins of tumor-associated macrophages and neutrophils

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death

  2012influential reference
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Transcriptional regulation of macrophage polarization: enabling diversity with identity

  2011cited by this paper
• Cancer: Macrophages limit chemotherapy

  2011cited by this paper
• Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts

  2011cited by this paper
• IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation

  2010cited by this paper
• Editorial: CSF1R, CSF‐1, and IL‐34, a “ménage à trois” conserved across vertebrates

  2010cited by this paper
• Recent advances in cancer therapy: an overview.

  2010cited by this paper
• A CREB-C/EBPβ cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair

  2009influential reference
• Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome

  2008cited by this paper
• Toll-like receptor–induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens

  2008cited by this paper
• PI3‐K/Akt‐dependent activation of cAMP‐response element‐binding (CREB) protein in Jurkat T leukemia cells treated with TRAIL

  2008cited by this paper
• Akt Involvement in Paclitaxel Chemoresistance of Human Ovarian Cancer Cells

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007cited by this paper
• Chemoresistance in solid tumours.

  2006cited by this paper
• Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer

  2006cited by this paper
• Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1

  2006cited by this paper
• Chemoresistance in non-small cell lung cancer.

  2005cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• AKT involvement in cisplatin chemoresistance of human uterine cancer cells.

  2004cited by this paper
• CSF-1 regulation of the wandering macrophage: complexity in action.

  2004cited by this paper
• NF-κB in cancer: from innocent bystander to major culprit

  2002cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002influential reference

• An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer

  2025cites this paper
• New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma

  2025cites this paper
• Role of IL‐34 in Tumors and Its Application to Regulate Inflammation

  2025cites this paper
• Integrating 12 Spatial and Single Cell Technologies to Characterise Tumour Neighbourhoods and Cellular Interactions in three Skin Cancer Types

  2025cites this paper
• Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer

  2025cites this paper
• Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances

  2025cites this paper
• Understanding the complexity of tumor-associated macrophages: Druggable and therapeutic insights

  2025cites this paper
• FOLR2+ macrophages in cancer: allies or enemies

  2025cites this paper
• Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition

  2025cites this paper
• The Involvement of IL-34 in Inflammatory and Malignant Skin Diseases.

  2025cites this paper
• Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation

  2025cites this paper
• Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy

  2025cites this paper
• Global research trends in tumor-associated macrophage studies: a bibliometric analysis

  2025cites this paper
• The clinical significance and potential therapeutic target of tumor-associated macrophage in non-small cell lung cancer

  2025cites this paper
• Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1

  2024cites this paper
• Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen‐processing‐presentation machinery and poor patient survival

  2024cites this paper
• AKAP12 positive fibroblast determines immunosuppressive contexture and immunotherapy response in patients with TNBC by promoting macrophage M2 polarization

  2024cites this paper
• Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation.

  2024cites this paper
• Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy

  2024cites this paper
• Drug resistance and tumor immune microenvironment: An overview of current understandings (Review)

  2024cites this paper
• Macrophage Colony Stimulating Factor (M-CSF) and Interleukin-34 (IL-34) Expression in Canine Osteosarcoma in the Context of the Tumour Immune Microenvironment.

  2024cites this paper
• Novel insights into immune cells modulation of tumor resistance.

  2024cites this paper
• IL-34 and its receptors as predictors of brain metastasis and prognosis in lung adenocarcinoma: Unveiling insights through bioinformatic and immunohistochemical investigations

  2024cites this paper
• Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade

  2024cites this paper
• Reprogramming Tumor-Associated Macrophage Using Nanocarriers: New Perspectives to Halt Cancer Progression

  2024cites this paper
• Tumor-associated macrophages affect the treatment of lung cancer

  2024cites this paper
• Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy

  2024cites this paper
• Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance

  2023cites this paper
• Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer.

  2023cites this paper
• Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth.

  2023cites this paper
• Quenching Thirst with Poison? Paradoxical Effect of Anticancer Drugs.

  2023cites this paper
• Tumor associated macrophages in esophageal squamous carcinoma: Promising therapeutic implications.

  2023cites this paper
• Enhancing Cancer Chemo‐Immunotherapy: Innovative Approaches for Overcoming Immunosuppression by Functional Nanomaterials

  2023cites this paper
• Interleukin 34 in Disease Progressions: A Comprehensive Review.

  2023cites this paper
• Role of IL-34 and its receptors in inflammatory diseases.

  2023cites this paper
• p53 gain-of-function mutation induces metastasis via Brd4-dependent Csf-1 expression.

  2023cites this paper
• Interleukin-34-NF-κB signaling aggravates myocardial ischemic/reperfusion injury by facilitating macrophage recruitment and polarization

  2023cites this paper
• Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy

  2023cites this paper
• A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin

  2023cites this paper
• Modulating multidrug resistance to drug-based antitumor therapies through NF-κB signaling pathway: mechanisms and perspectives

  2023cites this paper
• Targeting the tumor microenvironment: Potential strategy for cancer therapeutics.

  2023cites this paper
• Shedding light on macrophage immunotherapy in lung cancer

  2023cites this paper
• IL-34 and Immune Checkpoint Inhibitors Resistant through Macrophages: Pan-Cancer Overview

  2023cites this paper
• Cancer-associated fibroblasts: The chief architect in the tumor microenvironment

  2023cites this paper
• Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer

  2023influential citation
• Selective COX-2 Inhibitor Etoricoxib’s Liposomal Formulation Attenuates M2 Polarization of TAMs and Enhances its Anti-metastatic Potential

  2023cites this paper
• Highly triple-effective synergy based on tetrahedral DNA nanostructure-induced tumor vaccines for cancer therapy

  2023cites this paper
• DM-MOGA: a multi-objective optimization genetic algorithm for identifying disease modules of non-small cell lung cancer

  2023cites this paper
• Role of macrophages in tumor progression and therapy (Review)

  2022cites this paper
• Interleukin-34 cancels anti-tumor immunity by PARP inhibitor

  2022cites this paper
• M2-TAMs promote immunoresistance in lung adenocarcinoma by enhancing METTL3-mediated m6A methylation

  2022cites this paper
• Effective breast cancer therapy based on palmitic acid-loaded PLGA nanoparticles.

  2022cites this paper
• Interleukin-34-regulated T-cell responses in rheumatoid arthritis

  2022cites this paper
• Radiation-induced remodeling of the tumor-microenvironment through tumor cell-intrinsic expression of cGAS-STING in esophageal squamous cell carcinoma.

  2022cites this paper
• Self-Renewal of Macrophages: Tumor-Released Factors and Signaling Pathways

  2022cites this paper
• Prognostic value of lncRNAs related to fatty acid metabolism in lung adenocarcinoma and their correlation with tumor microenvironment based on bioinformatics analysis

  2022cites this paper
• Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer

  2022cites this paper
• Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator

  2022cites this paper
• Sanguinarine Regulates Tumor-Associated Macrophages to Prevent Lung Cancer Angiogenesis Through the WNT/β-Catenin Pathway

  2022cites this paper
• Targeting IL-34/MCSF-1R Axis in Colon Cancer

  2022cites this paper
• The ‘Danse Macabre’—Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes

  2022cites this paper
• Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression

  2022cites this paper
• Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils

  2022cites this paper
• The macrophage: a key player in the pathophysiology of peripheral neuropathies

  2022influential citation
• Tumour-associated macrophages heterogeneity drives resistance to clinical therapy

  2022cites this paper
• Characteristics of immunophenotypes and immunological in tumor microenvironment and analysis of immune implication of CXCR4 in gastric cancer

  2022cites this paper
• Tumor-Activated Carrier-Free Prodrug Nanoparticles for Targeted Cancer Immunotherapy: Preclinical Evidence for Safe and Effective Drug Delivery.

  2022cites this paper
• Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death

  2022cites this paper
• IL‐34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms

  2022cites this paper
• Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment

  2022cites this paper
• Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.

  2022cites this paper
• DDIT4 mediates the proliferation-promotive effect of IL-34 in human monocytic leukemia cells

  2021cites this paper
• The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis

  2021cites this paper
• Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.

  2021cites this paper
• IL‐34 and CSF‐1, deciphering similarities and differences at steady state and in diseases

  2021cites this paper
• Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma

  2021influential citation
• Extracellular Vesicle-Mediated Chemoresistance in Oral Squamous Cell Carcinoma

  2021cites this paper
• How Macrophages Become Transcriptionally Dysregulated: A Hidden Impact of Antitumor Therapy

  2021cites this paper
• Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis

  2021cites this paper
• Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance

  2021cites this paper
• The Hallmarks of Cancer as Ecologically Driven Phenotypes

  2021cites this paper
• Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer.

  2021cites this paper
• The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment

  2021cites this paper
• Furin-instructed aggregated gold nanoparticles for re-educating tumor associated macrophages and overcoming breast cancer chemoresistance.

  2021cites this paper
• Monocytes and macrophages in severe COVID‐19 – friend, foe or both?

  2021cites this paper
• Pathogenesis and therapeutic strategy in platinum resistance lung cancer.

  2021cites this paper
• Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles.

  2021cites this paper
• Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma

  2021cites this paper
• Interleukin-34 promotes tumorigenic signals for colon cancer cells

  2021cites this paper
• Exploration of the Molecular Characteristics of the Tumor–Immune Interaction and Analysis of Immune Implication of CXCR4 in Gastric Cancer

  2021cites this paper
• IL-34, the rationale of its expression in physiological and pathological condition.

  2021cites this paper
• E-cadherin on epithelial–mesenchymal transition in thyroid cancer

  2021cites this paper
• Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axis.

  2021cites this paper
• Therapeutic Targeting of the Tumor Microenvironment.

  2021cites this paper
• Cancer cell membrane-derived nanoparticles improve the activity of gemcitabine and paclitaxel on pancreatic cancer cells and coordinate immunoregulatory properties on professional antigen-presenting cells

  2020cites this paper
• Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade

  2020cites this paper
• Thrombin‐PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment

  2020cites this paper
• Communications Between Bone Marrow Macrophages and Bone Cells in Bone Remodeling

  2020cites this paper
• Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression

  2020cites this paper
• Bromodomain-containing protein 4 regulates interleukin-34 expression in mouse ovarian cancer cells

  2020cites this paper